BMO Capital Downgrades Horizon Therapeutics (HZNP) to Market Perform
Tweet
Share
E-mailGet Alerts HZNP Hot Sheet
Price: $116.30 --0%
Rating Summary:
10 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Rating Summary:
10 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
BMO Capital analyst Gary Nachman downgraded Horizon Therapeutics (NASDAQ: HZNP) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Horizon Therapeutics click here. For more ratings news on Horizon Therapeutics click here.
Shares of Horizon Therapeutics closed at $97.29 yesterday.
You May Also Be Interested In
- Piper Sandler Downgrades Southwestern Energy (SWN) to Neutral
- Morgan Stanley Downgrades Befesa SA (BFSA:GR) to Underweight
- Stifel Canada Downgrades Saipem (SPM:IM) (SAPMF) to Hold
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
